Tempest Therapeutics, Inc. — Board/Management Information 2015

Aug 27, 2015

8-K 1 a15-18623_18k.htm 8-K

*UNITED STATES SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934*

Date of report (Date of earliest event reported): August 27, 2015

*OvaScience, Inc.*

(Exact name of registrant as specified in its charter)

Delaware	001-35890	45-1472564
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

215 First Street, Suite 240 Cambridge, Massachusetts	02142
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 500-2802

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108702\15-18623-1\task7566138\18623-1-ba.htm',USER='108702',CD='Aug 27 17:04 2015'

*Item 5.02 (b): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.*

On August 27, 2015, David Harding and OvaScience, Inc. (the “Company”) mutually agreed that Mr. Harding will resign as Chief Commercial Officer of the Company effective August 28, 2015 to pursue other opportunities.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108702\15-18623-1\task7566138\18623-1-ba.htm',USER='108702',CD='Aug 27 17:04 2015'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OVASCIENCE, INC.
Date: August 27, 2015	/s/ Jeffrey E. Young
	Jeffrey E. Young
	Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\108702\15-18623-1\task7566138\18623-1-ba.htm',USER='108702',CD='Aug 27 17:04 2015'